Tetra Bio-Pharma taps Dalton Pharma Services to manufacture its coronavirus therapy ARDS-003 - Proactive Investors USA & Canada

Tetra Bio-Pharma Inc. (TSX-V:TBP) (OTCQB:TBPMF) CEO Guy Chamberland tells Proactive that Dalton Pharma Services will be developing a GMP batch manufacturing process to manufacture its coronavirus therapy ARDS-003.

Chamberland says this milestone achievement, where Tetra has found a way to make its drug injectable and stable for human use, will see Dalton scaling up production of the drug.

Let's block ads! (Why?)

Read Again https://www.proactiveinvestors.com/companies/news/927293/tetra-bio-pharma-taps-dalton-pharma-services-to-manufacture-its-coronavirus-therapy-ards-003-927293.html

Bagikan Berita Ini